Sequent Scientific Limited
NSE: SEQUENT · Pharma - CDMO/API
Snapshot
Unlock Sequent Scientific Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sequent Scientific Limited is a global animal health company specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. Its product portfolio covers a wide range of therapeutic areas including anthelmintics, anti-infectives, and nutraceuticals, alongside analytical testing services for the pharmaceutical and personal care sectors.
Business Model
The company generates revenue through the sale of animal health APIs and finished dosage forms, supported by a global manufacturing and distribution footprint. Additionally, it provides specialised analytical solutions, including method validation and stability testing, to external pharmaceutical and nutraceutical organisations.
Growth Outlook
Growth is driven by the expansion of its animal health product portfolio and the increasing demand for high-quality veterinary APIs and formulations globally. The company continues to leverage its analytical capabilities to support both internal development and external client requirements.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent global regulatory standards for pharmaceutical manufacturing and the potential for audits impacting production.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for APIs can significantly impact profit margins.
- Foreign Exchange Risk. As a global player with significant international operations, the company is exposed to currency fluctuations that may affect financial performance.
- Competitive Landscape. The animal health sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Sequent Scientific Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
18.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
25.0%
TTM · consolidated
P/E
61.9x
Q4 FY26 · consolidated
EV/EBITDA
19.1x
Q4 FY26 · consolidated
EBITDA MARGIN
249.8%
TTM · standalone
NET PROFIT MARGIN
9.1%
Q2 FY26 · standalone
DEBT TO EQUITY
0.7x
Q3 FY25 · consolidated
Peers · Pharma - CDMO/API
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sequent Scientific LimitedSEQUENT | 5,056 | 61.90 | 19.15 | -100.0% | 249.8% | 18.8% | 25.0% | — |
Glenmark Life Sciences LimitedGLS | 13,307 | — | 15.51 | 6.9% | 33.6% | 19.2% | 24.6% | — |
Jubilant Ingrevia Ltd.JUBLINGREA | 9,086 | 43.12 | 20.68 | 5.0% | 13.8% | 9.3% | 11.3% | -7.6% |
As of Q4 FY26
Financials
Sequent Scientific Limited
NSE: SEQUENT · Pharma - CDMO/API
Snapshot
Unlock Sequent Scientific Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sequent Scientific Limited is a global animal health company specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. Its product portfolio covers a wide range of therapeutic areas including anthelmintics, anti-infectives, and nutraceuticals, alongside analytical testing services for the pharmaceutical and personal care sectors.
Business Model
The company generates revenue through the sale of animal health APIs and finished dosage forms, supported by a global manufacturing and distribution footprint. Additionally, it provides specialised analytical solutions, including method validation and stability testing, to external pharmaceutical and nutraceutical organisations.
Growth Outlook
Growth is driven by the expansion of its animal health product portfolio and the increasing demand for high-quality veterinary APIs and formulations globally. The company continues to leverage its analytical capabilities to support both internal development and external client requirements.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent global regulatory standards for pharmaceutical manufacturing and the potential for audits impacting production.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for APIs can significantly impact profit margins.
- Foreign Exchange Risk. As a global player with significant international operations, the company is exposed to currency fluctuations that may affect financial performance.
- Competitive Landscape. The animal health sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Sequent Scientific Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
18.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
25.0%
TTM · consolidated
P/E
61.9x
Q4 FY26 · consolidated
EV/EBITDA
19.1x
Q4 FY26 · consolidated
EBITDA MARGIN
249.8%
TTM · standalone
NET PROFIT MARGIN
9.1%
Q2 FY26 · standalone
DEBT TO EQUITY
0.7x
Q3 FY25 · consolidated
Peers · Pharma - CDMO/API
As of Q4 FY26